A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer

NCT07137390 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped 0 participants enrolled

Conditions

Colorectal Cancer

Interventions

DRUG: Regorafenib
DRUG: Lorigerlimab

Sponsor

M.D. Anderson Cancer Center